Ally Therapeutics was an American biotechnology company based in Cambridge, Massachusetts. It was founded in 2018 and shut down in September 2021.[1]
History
Ally Therapeutics was spun out from George Church's lab at Harvard University in 2018. The company focused on developing “less immunogenic gene therapies.”[2] It received funding through Springboard Enterprises' Health Innovation Hub: Life Science in 2018.[3]
In July 2019, the company secured seed financing from Alta Partners, ARCH Venture Partners and UCB Ventures.[4]
External links
Ally Therapeutics shuts down. Global Venturing. Retrieved March 5, 2023, from http://archive.today/2023.03.05-012612/https://globalventuring.com/university/ally-therapeutics-shuts-down/ ↩︎
Ally Therapeutics. (2019, July 31). UCB Ventures. https://web.archive.org/web/20200922143412/https://ucbventures.com/sites/default/files/news-articles/Ally_Therapeutics_31_July_2019.pdf ↩︎
Portfolio. Springboard Enterprises. Retrieved December 14, 2022, from https://web.archive.org/web/20221214113825/https://sb.co/portfolio/ ↩︎
Liu, A. (2021, February 10). Biotech entrepreneur George Church launches gene therapy startup to design safer viral vectors. FierceBiotech. https://web.archive.org/web/20230305023409/https://www.fiercebiotech.com/research/george-church-s-new-gene-therapy-project-shields-viral-vectors-from-problematic-immune ↩︎
